Degradation And What It Means To The Supply Chain - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Degradation And What It Means To The Supply Chain


Pharmaceutical Technology Europe


Technology solutions

In many regions it is difficult to consistently monitor the factors that can influence drug degradation, but technology can help pharma manufacturers, distributors and others involved in the supply chain to screen products to determine if they are potentially substandard.

One of the most common technologies used today — besides laboratory testing — is the Global Pharma Health Fund's Minilab, which is used across 70 countries worldwide and leverages four types of tests to identify poor quality products. Pharmaceuticals containing less than 80% of the API will not pass the test. At just under $10000, Minilabs are relatively affordable, but require potable water, electricity and a conditioned-controlled environment where the testing is conducted.

Another option is spectroscopy, which has gained considerable momentum since becoming available in portable, handheld instruments. There are several technologies that use spectrometry, but I will focus on infrared (NIR) and Raman spectroscopy in particular because these techniques exist in handheld formats and don't require contact with a sample.

NIR is a well-known spectroscopic technique that measures molecular vibrations to identify individual chemical components of a drug or raw material. NIR requires an investment of manpower to create and maintain robust material libraries, but provides quick, reliable results once properly installed. It also has the advantage of not requiring contact with a sample. Compared with Raman spectroscopy, however, it has the disadvantage of being less selective and of requiring more up-front development work to build robust reference libraries.

Raman spectroscopy is less well known than NIR, but is becoming more popular because it is available as a portable, handheld instrument. These instruments can be used essentially by anyone because they quickly identify chemical components without coming into direct contact with the substance. In other words, handheld instruments can scan through sealed glass, plastic bottles, bags and blister packs at ports of inspection or any other place in the supply chain using a laser that illuminates a sample and measures the molecular shift. Handheld Raman spectroscopy is currently being used by a number of large pharmaceutical manufacturers, as well as regulatory bodies worldwide.

Conclusion

Pharmaceutical degradation may not have the visibility of counterfeiting, but it still poses a potential threat to patients and must be considered by pharma companies. Technology, however, can help ensure that substandard materials are removed from the supply chain and kept out of the hands of patients. Handheld Raman instruments represent a simplistic solution.

Duane Sword is vice president of Thermo Scientific's Portable Optical Analysis business unit.

References

1. J. Harris, P. Stevens and J. Morris, Keeping it real: combating the spread of fake drugs in poor countries (International Policy Network, May 2009).

2. P. Gumbel, "How to Stop the Counterfeit-Medicine Drugs Trade", Time (October, 2009). http://www.time.com/

3. FiercePharma Manufacturing, "Potency drops investigated in H1N1 vaccines" (January 2010). http://www.fiercepharmamanufacturing.com/


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here